Shire's treatment for primary immunodeficiency wins FDA approval
(Reuters) - Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.
The drug, Cuvitru, is already approved in 17 European countries, and the company expects to launch it in the United States in the coming weeks, Shire said on Wednesday.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.
